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Respiration is an automatic responseregulated by a network of neurons in
the hindbrain. These neurons control
the respiratory muscles and produce
pressure gradients that rhythmically
move air in and out the lungs. One of the
remarkable features of the respiratory
control system is its capacity to adjust
the rate of breathing to a variety of con-
ditions—a characteristic first described
more than a century ago. Thus, a
rise in the partial pressure of car-
bonic anhydride or oxygen depri-
vation (hypoxia) increases the rate
of ventilation, which then restores
the partial pressures of oxygen and
carbonic anhydride to their nor-
mal values. Failure to increase ven-
tilation in response to hypoxia can
be fatal; in particular, it can lead to
respiratory distress in newborns
and to obstructive sleep apnea (ces-
sation of breathing) in adults.
The molecular mechanisms by
which hypoxia leads to hyperven-
tilation are poorly understood1. In
the 13 September issue of Nature,
Lipton et al.2 make a convincing
case that the ventilatory response
to hypoxia is regulated by a group
of unsuspected players, deoxyhe-
moglobin-derived S-nitrosothiols
(SNOs).
Recent advances in our under-
standing of signaling through ni-
tric oxide (NO) have provided a
model whereby NO induces the S-
nitrosylation of a single critical
cysteine residue on different
classes of proteins, through a S-ni-
trosothiol–thiol exchange reac-
tion known as transnitrosation3,4.
According to the model, SNOs—rather
than NO—are the signaling molecules.
Consequently, SNO biochemistry has
become of central importance in eluci-
dating how NO regulates cellular func-
tions. Work carried out mainly by
Stamler’s group has demonstrated the
formation of S-nitrosohemoglobin in
the lung when red blood cells become
oxygenated, and the release of the SNO
group and formation of reactive SNO
molecules, such as S-nitrosoglutathione
(GSNO) during blood deoxygenation5.
The anion exchange protein 1 (AE1) in
the red blood-cell membrane appears to
facilitate the transport of the SNO group
from S-nitrosohemoglobin, across the
erythrocyte membrane, to glutathione
(GSH) dissolved in the plasma to form
GSNO (ref. 6). The beauty of this mecha-
nism is that signaling does not rely on
the free diffusion of NO, but instead the
generation of reactive SNOs molecules is
confined to specific sites.
Based on the findings described above
and on earlier work that connected NO
with breathing and oxygen tension7, as
well as the observation that GSNO is pre-
sent in the brain8, Lipton et al. hypothe-
sized that SNOs could be involved in the
ventilatory response to hypoxia. To
probe their hypothesis, the authors first
showed that a number of naturally oc-
curring SNOs increased ventilation in
freely behaving conscious rats. In these
experiments, Lipton et al. implanted a
dual cannula in close proximity of the
nucleus tractus solitarius (nTS) through a
hole drilled into the occipital skull of the
rats and, after the animals had recovered
from the intervention, measured the
ventilatory response to various agents.
The authors found that injection of 1
nmol S-nitroso-L-cysteine (L-
CSNO), S-nitrosocysteinyl-glycine
(CGSNO) or GSNO, but not S-ni-
troso-D-cysteine (D-CSNO), induced
a marked increase in the ventilation
rate. Moreover, the injection of the
synthetic NO donor S-nitroso-N-
acetylpenicillamine, was found to
have similar effects. The authors
also demonstrated that changes in
the respiratory rate in response to
the SNOs tested were similar to the
response observed after briefly ex-
posing the whole animal to hy-
poxia. In summary, these elegant
experiments demonstrate that SNOs
mimic the physiological ventilatory
response to hypoxia.
In a second set of experiments,
Lipton et al. observed that deoxy-
genated blood reacted with GSH to
form GSNO more efficiently than
oxygenated blood. Then, they
demonstrated that a low-mass com-
pound derived from deoxygenated
blood, identified as GSNO by mass
spectrometry, could reproduce the
ventilatory effect of hypoxia.
Interestingly, the authors observed
that pharmacological inhibition of
γ-glutamyl transpeptidase (γGT, an
enzyme that catalyzes the cleavage of
the γ-glutamyl moiety of GSNO to form
CGSNO) in the nTS abolished the venti-
latory response induced by GSNO, but
not the one induced by CGSNO. By gen-
erating a knockout mouse lacking γGT
and showing that the mutant animals
exhibit a marked alteration of hypoxic
ventilatory recovery, Lipton et al. con-
clusively demonstrate that γGT is re-
quired for the normal ventilatory
response to hypoxia.
The results of Lipton et al. reveal the
importance of SNOs as signaling mole-
NO, SNO and low O2
The respiratory control system responds to hypoxia by increasing the rate of breathing. The finding that
nitric-oxide–related molecules might control the ventilatory response to hypoxia suggests possible 
moleculartargets for the treatment of apnea.
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Fig. 1 Proposed mechanism by which GSNO controls the
ventilatory response to hypoxia. In hypoxia, the SNO from S-
nitrosohemoglobin (Hb-SNO) is transferred to GSH to form
GSNO in the vicinity of the neurons of the nTS, through a
process facilitated by the erythrocyte cell membrane anion
exchange protein 1 (AE1). Breakdown of newly synthesized
GSNO is then catalyzed by γGT. The CGSNO formed is then
split by a membrane-bound dipeptidase (DP). The resulting
S-nitrosocysteine (CSNO), through a transporter (T), is taken
into the neuron where it initiates a signaling process that in-
duces an increase in the rate of ventilation and restores the
partial pressure of oxygen to normal values.
Re
ne
e 
Lu
ca
s
©
20
01
 N
at
ur
e 
Pu
bl
is
hi
ng
 G
ro
u
p 
 h
ttp
://
m
ed
ic
in
e.
n
at
ur
e.
co
m
© 2001 Nature Publishing Group  http://medicine.nature.com
1108 NATURE MEDICINE • VOLUME 7 • NUMBER 10 • OCTOBER 2001
NEWS & VIEWS 
Fig. 1 The ubiquitin proteasome-mediated path-
way. 1) Activation of ubiquitin by E1. 2) Transfer of
the activated ubiquitin moiety from E1 to E2. 3)
Ubiquitin is further transferred in one of two ways.
3a) In the case of HECT-domain ligases (E3s), ubiq-
uitin generates a third, high-energy intermediate
with the ligase. 4a) Following specific recognition of
the substrate and generation of an E3–substrate
complex, multiple ubiquitin moieties are succes-
sively transferred to generate a substrate-anchored
polyubiquitin chain that serves as a recognition
marker for the 26S proteasome. 3b) In the case of
RING-finger domain E3s, a ternary complex is gen-
erated between the substrate, E3, and E2, and the
activated ubiquitin moieties are transferred directly
from E2 to the E3-bound substrate. 5 and 6)
Recycling of the E2s and E3s, respectively. 7)
Recognition of the polyubiquitin chain by the 19S
subcomplex of the 26S proteasome. 8)
Degradation of the substrate to generate peptides
with release of free and reusable ubiquitin.
cules that regulate the normal response
to hypoxia in vivo. The authors also pro-
vide evidence that the metabolism of
GSNO is similar to that of reduced glu-
tathione. Therefore, revisiting GSH bio-
chemistry might be helpful developing
a model of how signaling through
GSNO occurs (Fig. 1). Blood GSH is hy-
drolyzed by the membrane-bound en-
zyme γGT. The cysteinylglycine formed
is split by membrane-bound dipepti-
dases, and the resulting cysteine is
transported into a cell by a stereoselec-
tive transporter9). It is then possible that
GSNO formed in the proximity of nTS
during blood deoxygenation is first hy-
drolyzed by γGT to form CGSNO and
then to CSNO by a membrane-bound
dipeptidase (Fig. 1). Finally, through a
stereoselective transporter, L-CSNO but
not D-CSNO, would be taken inside the
neuron to initiate the signaling process
that leads to the control of ventilation,
probably through the S-nitrosylation of
specific target proteins. As CGSNO and
CSNO are very reactive, unstable mole-
cules, the confinement of the critical
components (γGT, dipeptidase and the
transporter) of GSNO metabolism to a
specific membrane compartment may
be critical for both specificity of target-
ing and propagation of the signal.
The components in the signaling
pathway that have been elegantly eluci-
dated by Lipton et al. will identify po-
tential targets to inhibit or increase the
effects of SNOs on the hypoxic re-
sponse and thereby provide treatments
for disorders such as sleep apnea.
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The ubiquitin- and proteasome-mediateddegradation of certain intracellular pro-
teins is fundamental to the regulation of
basic cellular processes, such as cell-cycle
progression, growth and differentiation, as
well as the immune and inflammatory re-
sponses. The ubiquitin proteolytic system
(UPS) also plays an important role in cellu-
lar quality control by removing mutated,
misfolded, unassembled or post-
translationally damaged proteins.
Recent work has implicated aberra-
tions of the UPS in the pathogenesis of
several neurodegenerative diseases and
in the formation of the inclusion bodies
that characterize many of these diseases.
Inclusion bodies, also termed Lewy bod-
ies (LBs), are proteinaceous cytoplasmic
inclusions that are enriched in disease-
characteristic proteins and ubiquitin,
some of which is conjugated to these
proteins. In this issue, Chung et al.1
demonstrate that parkin, a ubiquitin-
protein ligase that when mutated leads
to autosomal recessive juvenile parkin-
sonism (AR-JP), normally conjugates
ubiquitin to synphilin-1, an important
component of Parkinson disease (PD)
LBs. The study further attempts to link
this normal function of parkin to the
pathology that results from its inactiva-
tion. To understand this association, it
is important to understand the basic
functions and mode of action of the UPS
(Fig. 1).
Degradation via the UPS involves two
successive steps: tagging of the protein
substrate by covalent attachment of
multiple ubiquitin molecules, followed
by degradation of the tagged protein by
the 26S proteasome with release of free
and reusable ubiquitin, a reaction cat-
alyzed by ubiquitin C-terminal hydro-
lases (UCHs).
Linking ubiquitin, parkin and synphilin-1
One neuronal characteristic of Parkinson disease is the presence of Lewy bodies–intracytoplasmic accumulations of
protein. A new study draws a molecular link between the formation of these bodies, the ubiquitin protein
degradation system, parkin and synphilin-1. (pages 1144–1150) 
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